Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 19/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.54 |
| ▸ | MTOR | P42345 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2488150 | 0.82 | ATR (0.66) | ATRPIK3CAMTOR | |
| SCHEMBL2490083 | 0.80 | ATR (0.55) | ATRPIK3CAMTOR | |
| SCHEMBL2489967 | 0.79 | ATR (0.61) | ATRPIK3CAMTOR | |
| SCHEMBL2487135 | 0.79 | ATR (0.44) | ATRPIK3CAMTOR | |
| SCHEMBL3929192 | 0.78 | ATR (0.60) | ATRPIK3CAMTOR | |
| SCHEMBL3923817 | 0.78 | ATR (0.60) | ATRPIK3CAMTOR | |
| SCHEMBL3923841 | 0.76 | ATR (0.80) | ATRPIK3CAMTOR | |
| SCHEMBL1271464 | 0.75 | MTOR (0.62) | ATRKMT2APIK3CAMTOR | |
| SCHEMBL23848905 | 0.74 | ATR (0.58) | ATRPIK3CAMTOR | |
| SCHEMBL2491916 | 0.73 | ATR (0.52) | ATRKMT2APIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379530-A1 | PYRIMIDINE INDOLE DERIVATIVES FOR TREATING CANCER | AstraZeneca AB (SE) | 2011-10-26 | — | — | EP | disclosed |
| US-20110053923-A1 | CHEMICAL COMPOUNDS 610 | ASTRAZENECA (SE) | 2011-03-03 | — | — | US | disclosed |
| WO-2010073034-A1 | PYRIMIDINE INDOLE DERIVATIVES FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053923-A1 | CHEMICAL COMPOUNDS 610 | ABCG2, CYP3A7, CYP2C19 | ATR 2253/4885KMT2A 3348/4885PIK3CA 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.